.png)
Ciplostem, launched today by Cipla in partnership with Stempeutics Research, signals a strong move into orthobiologic medicine. The new MSC therapy enters the market as India faces a fast-growing burden of knee osteoarthritis, now affecting more...
Wockhardt Ltd. has made industry history today as the US FDA formally accepted its New Drug Application for Zaynich, marking the first time an Indian pharmaceutical company has achieved NDA acceptance for a New Chemical Entity...
Biotechnology is poised to significantly enhance Maharashtra's health sciences ecosystem, as the state government plans to establish a cutting-edge Life Sciences Innovation and Incubation Centre designed to expedite research and development within
Granules India Limited unveiled the inauguration of two cutting-edge Centres of Excellence at the Technology Research Park of IIT Hyderabad. These comprise the Ascelis Center of Excellence for Peptide Development
Nitin Stephen Abel, Senior Director at Terumo Interventional Systems, Terumo India, engaged in a conversation with Thiruamuthan, Assistant Editor at India Pharma Outlook, discusses India’s rapid evolution in interventional radiology—from diagnostic a
.png)
Lupin has obtained U.S. FDA approval of Armlupeg, a biosimilar of Neulasta. The product is pegfilgrastim 6mg/0.6ml prefilled injection in a single-dose syringe to be used as a subcutaneous injection. The manufacturing will be done in the biotech...
.jpeg)
Thermo Fisher Scientific, the world leader in serving science, today inaugurated two new facilities in Hyderabad’s Genome Valley. The Bioprocess Design Center (BDC) a technology scale-up facility was set up in partnership with Govt. Of Telangana; oth
Novo Nordisk’s obesity drug amycretin delivered a major boost to the company today, after new mid-stage trial results showed the treatment helped patients with type 2 diabetes lose up to 14.5% of their weight in 36 weeks. The update quickly...
Bayer reported a major step forward today as its experimental drug asundexian reduced the risk of recurrent ischemic stroke without increasing bleeding risk in a global phase III study. The OCEANIC-STROKE trial hit both its primary efficacy and...
Merck has secured a major win today as the US FDA approved KEYTRUDA and KEYTRUDA QLEX, used with Padcev, for adults with muscle-invasive bladder cancer (MIBC) who cannot receive cisplatin. This marks the first time a PD-1 inhibitor has been...
.jpg)
.jpg)
, CDSCO.jpg)